Triggering receptor expressed on myeloid cells 2
Triggering receptor expressed on myeloid cells 2 (TREM2) is a myeloid-cell surface receptor encoded by the TREM2 gene.
Triggering receptor expressed on myeloid cells 2 (TREM2) is a myeloid-cell surface receptor encoded by the TREM2 gene. It is expressed prominently in cells of the innate immune system, including microglia and macrophage populations, where it participates in sensing tissue damage, regulating inflammatory responses, and supporting cell survival and differentiation. In biomedical research, TREM2 is widely studied as a disease-associated immune regulator rather than as a classical enzyme or structural protein target.
TREM2 has attracted substantial attention in neurodegeneration, especially Alzheimer’s disease, where genetic variants are associated with increased risk and altered microglial function. It is also increasingly implicated in metabolic and fibrotic disease states, including Metabolic dysfunction associated steatohepatitis and liver fibrosis, where TREM2-expressing macrophage subsets appear to contribute to disease-associated immune remodeling. Because of these roles, TREM2 is being explored both as a mechanistic biomarker and as a therapeutic target.
Where the papers sit
10 papers from the last 6 months study triggering receptor expressed on myeloid cells 2 directly · updated from PubMed 6 Nov 2026
Study type 0 clinical trials · 2 human data · 5 preclinical · 3 unclassified
Themes 3 themes · 1 paradigm shift
-
Alzheimer's Disease Therapy
Small-molecule TREM2 agonism is moving from amyloid-stressed microglia and 5xFAD models toward clinical testing in Alzheimer's disease. VG-3927/SAR448851 is the leading example, with first-in-human evaluation alongside structural work defining an Aβ-overlapping binding site. Genetic studies of R47H and R62H TREM2 variants continue to clarify how impaired signaling worsens pathology. Cyclic peptides provide an additional route to modulate microglial responses, but their therapeutic relevance remains open.
4 papers · 40%
-
Macrophage Polarization and Phagocytosis
TREM2-linked macrophage states are being connected to phagocytosis, mitochondrial fitness and tissue fibrosis or inflammation. TREM2 deficiency can reduce M2 polarization and slow endometriosis, whereas iron starvation and mitochondrial failure impair Kupffer-cell function in MASH. H4K12 lactylation is implicated in generating TREM2high macrophages during liver fibrosis. The recurring question is how context-specific macrophage programming determines whether TREM2 activity protects tissue or sustains disease.
3 papers · 30%
-
Others — Cancer and Brain Injury
TREM2-related macrophage biology appears here in two separate settings: tumor-associated macrophages in cancer and post-ischemic brain injury. Cancer studies emphasize single-cell and spatial niches, CTLA-4-linked immune regulation and mRNA lipid nanoparticles designed to improve cytotoxic T-cell activity. The brain-injury study instead tests SS-31 plus NMN as a TREM2-directed neuroprotective strategy. These applications share interest in macrophage modulation but provide no single therapeutic trajectory across the cluster.
3 papers · 30%
TREM2 is not uniformly protective but can drive macrophage-mediated pathology
The ischemic-stroke MCAO/R mouse model treated TREM2-mediated signaling as neuroprotective, while the MASH liver study linked restoration of TREM2 abundance with embryonic Kupffer-cell homeostasis (PMIDs 42443448, 42310295). In contrast, the endometriosis mouse model found that TREM2 deficiency attenuated lesion progression by reducing M2 polarization and SIRPα-associated phagocytic suppression, and the multidrug-resistant melanoma study found TREM2-positive tumor-associated macrophages suppressing tumor-reactive CD8+ T cells and promoting tumor dedifferentiation; disrupting the TREM2-associated niche restored therapeutic sensitivity (PMIDs 42555090, 42748914). Together, these independent disease models replace the assumption that increasing or preserving TREM2 activity is generally beneficial with a context-dependent view in which TREM2 inhibition can be therapeutic when its macrophage program sustains immune suppression or lesion survival.
Papers
The 10 papers from the last 6 months that study triggering receptor expressed on myeloid cells 2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Alzheimer's Disease Therapy (4)
- Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer's disease. Science translational medicine · 14 Oct 2026 PMID 42873892
- Phage Display-Derived Cyclic Peptides Target TREM2 and Modulate Microglial Responses Under Amyloid Stress. ACS chemical neuroscience · 19 Aug 2026 PMID 42615638
- Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants. Acta neuropathologica · 15 Jun 2026 PMID 42298074
- Identification of a novel aβ-overlapping binding site on the TREM2 Ectodomain engaged by the small-molecule agonist VG-3927. Bioorganic & medicinal chemistry letters · 11 Jun 2026 PMID 42276260
Macrophage Polarization and Phagocytosis (3)
- TREM2 deficiency attenuates endometriosis progression by inhibiting M2 polarization of SpMs and suppressing SIRPα to enhance phagocytosis†. Biology of reproduction · 5 Aug 2026 PMID 42555090
- Labile iron starvation in embryonic Kupffer cells aggravates MASH via mitochondrial failure and macrophage dysfunction. Cell death & disease · 17 Jun 2026 PMID 42310295
- H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis. Hepatology (Baltimore, Md.) · 17 Jun 2026 PMID 42307631
Others — Cancer and Brain Injury (3)
- Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. Neurochemical research · 13 Jul 2026 PMID 42443448
By study type
Human data, design not indexed (2)
- Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants. Acta neuropathologica · 15 Jun 2026 PMID 42298074
- Identification of a novel aβ-overlapping binding site on the TREM2 Ectodomain engaged by the small-molecule agonist VG-3927. Bioorganic & medicinal chemistry letters · 11 Jun 2026 PMID 42276260
Preclinical: animal, cell and lab studies (5)
- Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer's disease. Science translational medicine · 14 Oct 2026 PMID 42873892
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Phage Display-Derived Cyclic Peptides Target TREM2 and Modulate Microglial Responses Under Amyloid Stress. ACS chemical neuroscience · 19 Aug 2026 PMID 42615638
- TREM2 deficiency attenuates endometriosis progression by inhibiting M2 polarization of SpMs and suppressing SIRPα to enhance phagocytosis†. Biology of reproduction · 5 Aug 2026 PMID 42555090
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. Neurochemical research · 13 Jul 2026 PMID 42443448
Unclassified: not yet indexed with MeSH (3)
- Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
- Labile iron starvation in embryonic Kupffer cells aggravates MASH via mitochondrial failure and macrophage dysfunction. Cell death & disease · 17 Jun 2026 PMID 42310295
- H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis. Hepatology (Baltimore, Md.) · 17 Jun 2026 PMID 42307631
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-07-16. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.